On April 26, 2022 Servier reported that treatment has gained official approval from China’s National Medical Products Administration (NMPA) to be used for patients with metastatic pancreatic cancer (Press release, Servier, APR 26, 2022, View Source [SID1234612954]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Pancreatic cancer is called the "emperor

Pancreatic cancer is called the "emperor of all cancers" due to its insidious symptoms, high degree of malignancy and high fatality rate. There were 124,994 new cases of pancreatic cancer and 121,853 deaths in China in 2020[1]. Thus, there are huge needs for treatment options as the incidence of pancreatic cancer is increasing year by year.

No other treatment for pancreatic cancer indications had become available in Mainland China since 1999. There is still a high unmet medical need for the treatment of pancreatic cancer.

For Stephane Mascarau, General Manager of Servier Tianjin Pharmaceutical, "This approval marks an important step forward for Servier to play a key role in oncology in China".

As cancer is the second leading cause of death worldwide2, Servier’s ambition is to become a recognized player in oncology, initiating therapeutic progress where the need is greatest. Therefore, the Group dedicates more than 50% of its R&D budget to this field.